At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Apr 30, 2026 at 16:30 ET
Emergent BioSolutions reported Q1 2026 adjusted net income per diluted share of $0.21, beating the consensus estimate of -$0.25, but total revenues fell 30% YoY to $156.1M, below the $160.5M consensus. The company raised its full-year 2026 adjusted EBITDA guidance to $155-$175M (from $135-$155M) and adjusted net income guidance to $45-$65M (from $25-$45M), while keeping revenue guidance unchanged at $720-$760M.
- Q1 2026 total revenues of $156.1M, down 30% YoY from $222.2M
- Q1 2026 GAAP net income of $6.8M ($0.07 diluted EPS), down 90% from $68.0M ($1.19 diluted EPS)
- Adjusted net income per diluted share of $0.21, beating consensus of -$0.25
- Adjusted EBITDA of $35.6M, down 55% from $79.1M YoY
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access